A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit Therapeutics said their experimental lung cancer drug reduced the risk of death by 34% in a late-stage trial. The result is a meaningful clinical efficacy signal and could improve the commercial outlook for the program if further regulatory steps proceed successfully. The news is likely to support sentiment in the individual names and broader oncology biotech space.

Analysis

Akeso and Summit Therapeutics said their experimental lung cancer drug reduced the risk of death by 34% in a late-stage trial. The result is a meaningful clinical efficacy signal and could improve the commercial outlook for the program if further regulatory steps proceed successfully. The news is likely to support sentiment in the individual names and broader oncology biotech space.